Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

- Company on Target to File NDA in Second Quarter of 2008 -

CORONA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced positive results today from its Phase 3 study of oxybutynin topical gel (OTG) in patients with overactive bladder (OAB). The study met its primary endpoint of a statistically significant reduction in incontinence episodes, and secondary endpoints of reduction in frequency and increases in void volume compared with placebo, while demonstrating a low incidence of side effects.

"We are extremely encouraged with the results from this trial which will support our NDA submission, and we are on track to file with FDA in the second quarter of 2008," said Paul Bisaro, Watson's President and Chief Executive Officer. "Additionally, we have the potential to introduce the first gel formulation for the treatment of overactive bladder in 2009."

"Offering patients the ease and comfort of a daily gel for the treatment of OAB may provide greater patient acceptability and persistence on treatment," said Peter K. Sand, M.D., director of the Evanston Continence Center, Evanston Northwestern Healthcare, Northwestern University, Feinberg School of Medicine and Professor of Obstetrics and Gynecology and Director of the Division of Urogynecology, Evanston, IL.

It is well recognized that transdermal delivery of oxybutynin is a safe and effective treatment for OAB. By delivering oxybutynin transdermally, first-pass gastric and hepatic metabolism is bypassed, which is believed to result in lower anticholinergic side effects such as dry mouth and constipation. These side effects result in a significant level of patient non-compliance a
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... , May 16, 2013  HeartWare International, Inc. (NASDAQ: ... of less invasive, miniaturized circulatory support technologies that are revolutionizing ... Doug Godshall is scheduled to present ... EDT on Monday, May 20, 2013.  The conference is being ... A live webcast of the Company,s presentation at ...
(Date:5/16/2013)... , May 16, 2013  Amgen (NASDAQ: AMGN ... on Tuesday, May 21, 2013, at the Sheraton New York ... beginning at 10:00 a.m. Eastern Daylight Time. Joseph ... Research and Development at Amgen, will present at the conference. ... Events Calendar on Amgen,s website, www.amgen.com , under Investors. ...
(Date:5/16/2013)... -- OrthoView PSL will allow individual surgeons ... widely-used OrthoView digital templating software via the Cloud and ... started. OrthoView, the leading independent provider of ... dedicated to enabling orthopaedic surgeons in hospitals and private ... film is unavailable. Over 5,000 orthopaedic surgeons in the ...
Breaking Medicine Technology:HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2
... Medical, Inc. (OTCBB: AEMD), the pioneer in developing ... cancer, announced today the introduction of HER2osome™, a ... of HER2+ breast cancer, which is characterized by ... over-expression of HER2 protein.  Breast cancer represents the ...
... Sept. 21, 2011 Reportlinker.com announces that a ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619264/Generic-Drugs-The-Global-Market-Focus-on-the-Americas.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... examination of the strategies employed by companies specializing ...
Cached Medicine Technology:Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 2Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 3Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 4Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer 5Generic Drugs: The Global Market: Focus on the Americas 2Generic Drugs: The Global Market: Focus on the Americas 3Generic Drugs: The Global Market: Focus on the Americas 4Generic Drugs: The Global Market: Focus on the Americas 5Generic Drugs: The Global Market: Focus on the Americas 6Generic Drugs: The Global Market: Focus on the Americas 7Generic Drugs: The Global Market: Focus on the Americas 8Generic Drugs: The Global Market: Focus on the Americas 9Generic Drugs: The Global Market: Focus on the Americas 10
(Date:5/18/2013)... Minn. -- Regular consumption of coffee is associated ... (PSC), an autoimmune liver disease, Mayo Clinic research ... Digestive Disease Week 2013 conference in Orlando, Fla. ... the bile ducts that results in inflammation and ... the liver, liver failure and biliary cancer. , ...
(Date:5/18/2013)... May 18, 2013 Today, Zane ... insurance agents’ role in Marketplaces . Zane Benefits, ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to ... Human Services (HHS) recently released a much-anticipated statement ...
(Date:5/18/2013)... 2013 The “World Healthcare IT Market: ... the major market drivers, restraints, and opportunities in North ... Browse , 89 market data ... on "Healthcare IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html ... reports. , The global healthcare IT market is expected ...
(Date:5/18/2013)... 2013 As metal-on-metal hip implant ... country, Bernstein Liebhard LLP notes that a new study ... tissue damage before they experience any pain from a ... Daily will appear in the Journal of Bone & ... screens of their hips. The researchers found tissue ...
(Date:5/18/2013)... The “Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, ... Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive ... major market drivers, restraints, and opportunities in North America, ... , 147 market data tables ... 318 pagesand in-depth TOC of “Sleep Apnea ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3
... at the Queensland Institute of Medical Research (QIMR) and the ... and successfully treated it by performing an experimental stem cell ... and out of hospital Katie Pulling had almost given up ... hearing the doctors say, ,We don,t know what is wrong, ...
... the forefront of HIV prevention research will be taking center ... L. Lawrence Convention Center in Pittsburgh May 22-25. M2010 ... community advocates and experts in global health who are working ... of the world. Nearly 1,000 participants from 47 countries will ...
... ... to look for. Flexible Assembly Systems uncovers the great torque screwdriver mystery with its very ... ... you don’t know what to look for. A torque screwdriver comes in many different ...
... controlled severe disease using less medication , MONDAY, May ... be a mouse click away, Dutch researchers report. , ... program maintained long-term control of severe asthma but needed ... do so, the study found. , "We know that ...
... researchers say , MONDAY, May 17 (HealthDay News) -- ... organophosphate pesticides, commonly found on berries, celery and other ... (ADHD) in children. , At this point, though, there ... ADHD, stated the authors of a paper appearing in ...
... Fighting ... takes is one look at the brand and the name to get an instant smile and chuckle. ... , ... Drink (FCE) is a concept that was born on the cusp of the energy drink boom that ...
Cached Medicine News:Health News:Australian researchers identify a new disease 2Health News:Press briefings at International Microbicides Conference May 22-25 2Health News:Press briefings at International Microbicides Conference May 22-25 3Health News:Press briefings at International Microbicides Conference May 22-25 4Health News:Press briefings at International Microbicides Conference May 22-25 5Health News:Flexible Assembly Systems Announces Torque Screwdriver Application Guide 2Health News:Web-Based Program Can Boost Asthma Care 2Health News:Pesticides on Produce Tied to ADHD in Children 2Health News:Pesticides on Produce Tied to ADHD in Children 3Health News:Unique Marketing Approach to the Energy Drink Market Brings Explosive Response 2
... Our Buffered Wright-Giemsa Stain is ... contains the fixative, buffer, and ... staining of blood smears. It ... bottle for ease of use ...
This Wright-Giemsa is a dual-use stain for peripheral blood and bone marrow smears. It produces somewhat darker results when compared with Giemsa, particularly in the blue to magenta shades....
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCP). Storage temp: 15 - 30 C. Linearity: 0.5 - 8.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 250 number of tests....
Medicine Products: